These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574 [TBL] [Abstract][Full Text] [Related]
3. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Cunningham D; Sirohi B; Pluzanska A; Utracka-Hutka B; Zaluski J; Glynne-Jones R; Koralewski P; Bridgewater J; Mainwaring P; Wasan H; Wang JY; Szczylik C; Clingan P; Chan RT; Tabah-Fisch I; Cassidy J Ann Oncol; 2009 Feb; 20(2):244-50. PubMed ID: 18854549 [TBL] [Abstract][Full Text] [Related]
5. Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer. Kuebler JP; de Gramont A Semin Oncol; 2003 Aug; 30(4 Suppl 15):40-6. PubMed ID: 14523794 [TBL] [Abstract][Full Text] [Related]
6. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076 [TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients. Bajetta E; Beretta E; Di Bartolomeo M; Cortinovis D; Ferrario E; Dognini G; Toffolatti L; Buzzoni R Oncology; 2004; 66(2):132-7. PubMed ID: 15138365 [TBL] [Abstract][Full Text] [Related]
9. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325 [TBL] [Abstract][Full Text] [Related]
10. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer. Fisher MD Clin Colorectal Cancer; 2001 Aug; 1(2):85-6. PubMed ID: 12445365 [No Abstract] [Full Text] [Related]
11. [New therapeutic options in chemotherapy of advanced colorectal cancer]. Reimer P; Rückle-Lanz H Med Klin (Munich); 2001 Oct; 96(10):593-8. PubMed ID: 11715331 [TBL] [Abstract][Full Text] [Related]
12. Current treatments and future perspectives in colorectal and gastric cancer. Wilke HJ; Van Cutsem E Ann Oncol; 2003; 14 Suppl 2():ii49-55. PubMed ID: 12810459 [TBL] [Abstract][Full Text] [Related]
13. Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer. Wasserman E; Sutherland W; Cvitkovic E Clin Colorectal Cancer; 2001 Nov; 1(3):149-53. PubMed ID: 12450427 [TBL] [Abstract][Full Text] [Related]
14. Current status of capecitabine in the treatment of colorectal cancer. Rothenberg ML Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635 [TBL] [Abstract][Full Text] [Related]
15. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. McCleary NJ; Meyerhardt JA; Green E; Yothers G; de Gramont A; Van Cutsem E; O'Connell M; Twelves CJ; Saltz LB; Haller DG; Sargent DJ J Clin Oncol; 2013 Jul; 31(20):2600-6. PubMed ID: 23733765 [TBL] [Abstract][Full Text] [Related]
17. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715 [TBL] [Abstract][Full Text] [Related]
18. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. Braun MS; Richman SD; Thompson L; Daly CL; Meade AM; Adlard JW; Allan JM; Parmar MK; Quirke P; Seymour MT J Clin Oncol; 2009 Nov; 27(33):5519-28. PubMed ID: 19858398 [TBL] [Abstract][Full Text] [Related]
19. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?]. Carnaghi C; Zucali P; Garassino I Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. Hejna M; Köstler WJ; Raderer M; Tomek S; Brodowicz T; Scheithauer W; Wiltschke C; Zielinski CC Anticancer Drugs; 2000 Sep; 11(8):629-34. PubMed ID: 11081454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]